 Home > Active Ingredient News > Antitumor Therapy > JTO: Three-region and two-region lymph node dissection for middle and lower esophageal cancer: long-term results of a randomized clinical trial.

JTO: Three-region and two-region lymph node dissection for middle and lower esophageal cancer: long-term results of a randomized clinical trial.

 Last Update: 2021-03-19
 Source: Internet
 Author: User

Tags

solve 2 3

gentian violet cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Esophageal cancer is known for its early and distant lymph node metastasis (LNM).

The purpose of radical lymph node dissection during esophageal cancer resection is to reduce recurrence and improve survival.

In order to evaluate the role of three-region lymph node dissection in the treatment of esophageal cancer, the researchers in this article initiated a randomized trial in 2013 to compare the results of three-field and two-field lymph node dissection during esophagectomy.

In this study, from March 2013 to November 2016, a total of 400 middle and lower thoracic esophageal cancer patients were enrolled and randomly assigned to undergo esophagectomy.

The demographic characteristics of the two studies were similar.

In summary, for patients with middle and lower thoracic esophageal cancer, there is no improvement in OS or DFS after esophagectomy with three-regional lymph node dissection compared to the second with its lymph node dissection.

For patients with middle and lower thoracic esophageal cancer, there is no improvement in OS or DFS after esophagectomy with three-regional lymph node removal compared with two with its lymph node removal.

Li, Bin et al.
Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
Journal of Thoracic Oncology, Volume 16, Issue 2, 310-317 Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.